SightfileU.S. market data from official filings

Companies › NRXP

NRX PHARMACEUTICALS INC (NRXP)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001719406 · EDGAR filings · Updated 2026-07-22

NRX PHARMACEUTICALS INC (NRXP) has reported institutional ownership of 18.6%, with 32 institutional managers holding positions valued at $13.2M per the latest 13F reporting period. SEC filings include an active non-reliance notice on previously issued financial statements (8-K Item 4.02), notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings, triggering event that accelerates or increases a direct financial obligation (8-K Item 2.04).

Institutional ownership
18.6%
Institutional managers
32
Reported 13F value
$13.2M
Data flags
4 active
from SEC filings

Filings this week (1)

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, NRX PHARMACEUTICALS INC has 32 institutional holders and institutional ownership of 18.6%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 1 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2026-05-15 (recurring since 2023-03-31) — source filing. The authoritative details are those stated in the filing itself.
Active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), most recently filed 2026-01-16 (recurring since 2020-02-14) — source filing. The authoritative details are those stated in the filing itself.
Active triggering event that accelerates or increases a direct financial obligation (8-K Item 2.04), most recently filed 2024-04-30 (recurring since 2024-04-30) — source filing. The authoritative details are those stated in the filing itself.
Active non-reliance notice on previously issued financial statements (8-K Item 4.02), most recently filed 2022-08-12 (recurring since 2021-05-11) — source filing. The authoritative details are those stated in the filing itself.

Related companies

POLYPID LTD (PYPD) · PALATIN TECHNOLOGIES INC (PTN) · Alpha Pro Tech Ltd (APT) · ANIXA BIOSCIENCES INC (ANIX) · KAZIA THERAPEUTICS LTD (KZIA) · ATARA BIOTHERAPEUTICS COM NEW (ATRA)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-22.